Flag of the European Union EU Clinical Trials Register Help

Clinical trials for True positive rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,874 result(s) found for: True positive rate. Displaying page 1 of 94.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-003944-23 Sponsor Protocol Number: UFK-HEF 5 Start Date*: 2005-04-20
    Sponsor Name:Medical University of Vienna
    Full Title: Acetyl salicylic acid in the treatment of patients with positive margins after surgery for cervical dysplasia grade II-III: A phase II trial
    Medical condition: Cervical intraepithelial neoplasia grade II/III with positive margin after surgery
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006700-32 Sponsor Protocol Number: 80013 Start Date*: 2022-07-13
    Sponsor Name:Meander Medical Centre
    Full Title: A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using submucosal bevacizumab-800CW.
    Medical condition: Colon carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006796-41 Sponsor Protocol Number: 80117 Start Date*: 2022-07-13
    Sponsor Name:Meander Medical Centre
    Full Title: A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CW
    Medical condition: Colon carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006570-23 Sponsor Protocol Number: FAPI-POLMONE-2021 Start Date*: 2022-03-17
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: The Role Of The New Promising Oncological Pet/Ct Tracer [68Ga] Ga-Fapi For Staging Lung Cancer: A Preliminary Study
    Medical condition: suspected / newly diagnosed lung cancer in staging, patients already on a conventional staging diagnostic path (including FDG-PET / standard CT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005140-18 Sponsor Protocol Number: RAME-01 Start Date*: 2015-11-12
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI
    Medical condition: Prostate cancer patients who showed biochemical relapse after surgery or first-line treatment with radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003693-27 Sponsor Protocol Number: CHDR1854 Start Date*: 2019-02-06
    Sponsor Name:Leiden University Medical Center
    Full Title: Intraoperative near-infrared fluorescence imaging of endometriosis with OTL38: a pilot study
    Medical condition: Endometriosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003560-13 Sponsor Protocol Number: OTL-2016-OTL38-005 Start Date*: 2017-10-18
    Sponsor Name:On Target Laboratories, LLC
    Full Title: A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
    Medical condition: adenocarcinoma lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004879-36 Sponsor Protocol Number: 100450 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of H...
    Medical condition: Vaccination of healthy newborns of HBsAg+ and/or HBeAg+ mothers against Hepatitis.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000423-14 Sponsor Protocol Number: D1532C00065 Start Date*: 2013-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Diff...
    Medical condition: Differentiated Thyroid Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002132-10 Sponsor Protocol Number: MO27775 Start Date*: 2012-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patien...
    Medical condition: HER2- and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000748-26 Sponsor Protocol Number: PM0259CA215B0 Start Date*: 2004-11-08
    Sponsor Name:Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament
    Full Title: Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.
    Medical condition: Treatment in women with previously untreated HER2 positive metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002781-23 Sponsor Protocol Number: DAP-PEDS-07-02 Start Date*: 2015-06-29
    Sponsor Name:Cubist Pharmaceuticals, Inc
    Full Title: An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who are Concurrently Receiving Standard Antibiotic Therapy for Pro...
    Medical condition: Gram-positive Infection
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022120-72 Sponsor Protocol Number: JF-001 Start Date*: 2010-12-17
    Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust
    Full Title: The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs).
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    14.1 10022891 - Investigations 10020180 HIV positive LLT
    14.1 10022891 - Investigations 10020188 HIV test positive PT
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017775-19 Sponsor Protocol Number: CAMN107EIC01 Start Date*: 2010-05-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
    Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-004255-20 Sponsor Protocol Number: CHDR1848___OTL-2016-OTL38-006 Start Date*: 2019-02-26
    Sponsor Name:On Target Laboratories, LLC
    Full Title: A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003780-50 Sponsor Protocol Number: B1871008 Start Date*: 2008-07-30
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
    Medical condition: Chronic myelogenous leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) BE (Completed) ES (Completed) LV (Completed) LT (Completed) FR (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000968-34 Sponsor Protocol Number: CAMN107ADE20 Start Date*: 2015-10-07
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years o...
    Medical condition: The trial aims to evaluate the efficacy and quality of life of nilotinib 300mg BID in patients with chronic myleoid leukemia in chronic phase.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002556-24 Sponsor Protocol Number: CLEE011XDE01 Start Date*: 2016-10-14
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) i...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003689-41 Sponsor Protocol Number: CRAD001YGB11 Start Date*: 2012-11-19
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e...
    Medical condition: oestrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002629-23 Sponsor Protocol Number: 100449 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-Hepatitis B vaccine (10 µg) in newborns of Hepa-titis B envelope antigen positive (HBeAg+) and Hepatitis B surface antigen...
    Medical condition: Hepatitis B vaccination in healthy newborns of HBeAg+ and HBsAg+ mothers
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 23:25:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA